McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in an April 1, 2013 Law360.com article entitled, “Virginia Law Raises Red Flags For Biosimilar Industry.” Virginia’s new law restricting a pharmacist’s ability to swap a biosimilar for a pricey name-brand biologic drug is the first of what could likely become many state laws limiting access to biosimilars, experts say, posing a new threat to the fledgling industry before it even gets off the ground. View the article